Načítá se...
Intravenous zoledronate for osteoporosis: less might be more
Annual administration of 5 mg intravenous zoledronate is moderately effective in reducing fracture risk in older adults, decreasing the relative risk of clinical fracture by 33%. However, almost 10 years after its approval for use in clinical practice there remain very substantial uncertainties abou...
Uloženo v:
| Vydáno v: | Ther Adv Musculoskelet Dis |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4959627/ https://ncbi.nlm.nih.gov/pubmed/27493690 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1759720X16650866 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|